Yup its comparing apples to oranges. I was in a meeting yesterday with a TEVA Product Manger discussing this very thing. When Cephalon was acquired TEVA also received Cima Labs a delivery system company. Business development and upper management are currently negotiating a molecule to leverage this delivery system technology.
If the delivery system is worth its salt there is a decent chance pharma companies will be interested as we are seeing. Thus far the interest has been in the OTC markets but its new and OTC is a cake walk compared to navigating the land mines and obstacles of any pharmaceutical trial.
Like I said these guys know what they are doing and they are good at what they do. But it is still a penny stock and with that comes the penny stock advice and I guess you don't get one without the other
News 
Market Data 
Discover 
AI
